Lieselotte Verlinden

Learn More
BACKGROUND & AIMS We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections. METHODS We performed a randomized, multicenter, partially blinded study of patients (23 with HCV genotype 2,(More)
  • 1